SNDX — Syndax Pharmaceuticals Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1395937 ·
Last close
$9.20
Market Cap
$828.26M
52W High
$25.59
52W Low
$9.03
ADV30
3,590,557
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 83,298,000 | 69,302,000 | -41,895,000 | -49,433,000 | 692,671,000 | 135,941,000 | 709,851,000 |
| Jun 2026 | 72,788,000 | 69,580,000 | -39,995,000 | -49,363,000 | 703,652,000 | 336,477,000 | 688,553,000 |
| Mar 2026 | 64,864,000 | 62,231,000 | -34,202,000 | -42,673,000 | 472,668,000 | 130,893,000 | 431,046,000 |
| Dec 2025 | 68,728,000 | 66,022,000 | -62,548,000 | -68,014,000 | 529,706,000 | 134,930,000 | 465,076,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-177,359,000
Investing CF
$-73,417,000
Financing CF
$269,794,000
CapEx
$-56,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.36
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,648,049,000
Inventory
$39,376,000
Receivables
$79,782,000
ST Investments
$291,163,000
EBIT TTM
$-162,390,000
Pretax Income TTM
$-209,483,000
Interest Exp TTM
$47,093,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$289,678,016
EBITDA
$-178,622,000
Free Cash Flow
$-113,034,128
Enterprise Value
$1,011,027,584
Total Cash
$437,256,992
Total Debt
$589,414,976
Shares Out
90,028,256
Trailing EPS
$-2.37
Book Value
$-0.19
ROE
-426.4%
ROA
-17.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 172,352,000 | -273,084,000 | -285,422,000 | 529,706,000 | 465,076,000 | 64,630,000 | -322,980,000 |
| Dec 2024 | 23,680,000 | -339,672,000 | -318,758,000 | 724,816,000 | 436,692,000 | 288,124,000 | -274,903,000 |
| Dec 2023 | 0 | -229,954,000 | -209,360,000 | 612,880,000 | 58,684,000 | 554,196,000 | -160,601,000 |
| Dec 2022 | 0 | -151,757,000 | -149,338,000 | 497,236,000 | 29,787,000 | 467,449,000 | -133,675,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$252,004,000
NetIncome TTM
$-220,765,000
OpCashFlow TTM
—
Assets (Latest)
$703,652,000
Forward EPS
$-0.83
Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $17.00 · spot: $8.56 · call volume: 94 · put volume: 1,560
Expected Move to 2028-01-21:
±$4.56
(53.27%) —
implied range
$4.00 –
$13.12
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ORIC | Oric Pharmaceuticals, Inc. | $829.22M | $8.00 | — |
| CTY | CITY THERAPEUTICS, INC. | $846.44M | $17.50 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $808.18M | $42.92 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $806.23M | $4.87 | — |
| PHAR | Pharming Group N.V. | $853.58M | $12.06 | — |
News headlines (Yahoo Finance, 1h cache)
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2026-11-09 22:26 · Yahoo
Why Is Syndax Pharmaceuticals (SNDX) Drawing So Much ASH 2026 Attention?
2026-11-05 22:14 · Yahoo
Syndax Pharmaceuticals Inc (SNDX) (Q3 2026) Earnings Call Highlights: Revenue Surges 82% as ...
2026-11-05 05:01 · Yahoo
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-11-04 21:01 · Yahoo
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
2026-11-04 14:01 · Yahoo
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
2026-11-04 14:00 · Yahoo
Syndax Pharmaceuticals Stock Gains Focus After Revenue Growth And Pipeline Progress
2026-11-04 00:25 · Yahoo
Syndax Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-03 13:30 · Yahoo
Syndax Pharmaceuticals (SNDX) Stock May Be Rich After Revuforj Award Win
2026-11-03 08:08 · Yahoo
Syndax Pharmaceuticals (SNDX) Missed On Q3 Results, Is The 65% Undervaluation Case Still Intact?
2026-11-03 06:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.